Does Zepbound Reduce Binge Eating?
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight plus weight-related conditions, but not specifically for binge eating disorder (BED). Clinical evidence shows it reduces binge eating episodes in patients with moderate to severe BED alongside obesity. In a phase 2 trial published in the New England Journal of Medicine, 80% of participants on the highest tirzepatide dose (15 mg weekly) achieved remission of binge eating episodes (zero episodes in the prior month) after 12 weeks, compared to 22% on placebo.[1] Participants lost an average of 13.5% body weight on that dose.
How Does Tirzepatide Affect Appetite and Binge Behaviors?
Tirzepatide mimics GLP-1 and GIP hormones, slowing gastric emptying, signaling fullness to the brain, and regulating reward pathways linked to overeating. This curbs compulsive binge urges, with trial data showing 90-100% of treated patients had at least a 75% drop in binge days per week.[1] Remission rates held at 72-79% through 36 weeks in extended data.
Is It Approved or Used Off-Label for BED?
No FDA approval for BED treatment; it's labeled for weight loss only. Psychiatrists sometimes prescribe off-label based on trial results, especially for obese BED patients unresponsive to standard therapies like cognitive behavioral therapy or Vyvanse (lisdexamfetamine, the only FDA-approved BED drug).[2] Coverage varies—insurance may deny for BED alone without obesity.
Compared to Other Weight Loss Drugs for Binge Eating
| Drug | BED-Specific Approval | Binge Reduction Evidence | Weight Loss Edge |
|------|-------------------------|---------------------------|------------------|
| Zepbound (tirzepatide) | No | Strong phase 2 data: 80% remission[1] | Highest (~20% body weight in obesity trials) |
| Wegovy (semaglutide) | No | Moderate; smaller binge-focused studies | ~15% body weight |
| Vyvanse | Yes | 40% remission in trials[2] | Minimal weight loss |
| Contrave (naltrexone/bupropion) | No | Some reduction; weaker data | ~5-10% body weight |
Zepbound outperforms on weight but lacks Vyvanse's BED nod.
Patient Experiences and Real-World Use
Online forums like Reddit report reduced binge frequency, with users citing fewer "food noise" episodes, though some note initial GI side effects disrupting eating patterns. Long-term adherence is key; dropout rates were low (6%) in BED trials.[1]
Risks and When to Avoid It
Common side effects include nausea (30-40%), diarrhea, and vomiting, which may temporarily worsen disordered eating perceptions. Rare risks: gallbladder issues, pancreatitis. Not studied in non-obese BED patients. Consult a doctor—it's contraindicated in medullary thyroid cancer history or pregnancy.[3] No head-to-head trials vs. BED standards yet.
[1]: NEJM - Tirzepatide for Binge Eating Disorder
[2]: FDA - Vyvanse for BED
[3]: Zepbound Prescribing Information